Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Effect of rehabilitation therapy on the motor functions in patients with multiple system atrophy
Objective: We aim to evaluated the effect of rehabilitation therapy on the motor symptoms and activities of daily living in patients with MSA using an…TOPAS-MSA: Targeting Oligomer Pathology of Alpha-Synuclein – A Study Evaluating the Safety and Efficacy of Emrusolmin in Patients with Multiple System Atrophy
Objective: The objective of the TOPAS-MSA study is to assess the safety and efficacy of emrusolmin (anle138b/TEV-56286), an orally bioavailable small molecule targeting aggregated α-synuclein,…Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial
Objective: Assess the efficacy and safety of monthly IV infusions with the anti-alpha synuclein [a-syn] monoclonal antibody Lu AF82422 for the treatment of patients with…Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation
Objective: Assess brain volume changes in patients with multiple system atrophy (MSA) over one year. Background: Identifying disease progression biomarkers is crucial for advancing MSA…Identifying a path to improve diagnostic delay and access to care for PSP, CBS, and MSA
Objective: To understand diagnosis and care experiences of patients and care partners living with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy…Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422
Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…A multiple-dose thorough QT study to evaluate the effect of ampreloxetine on cardiac repolarization in healthy subjects
Objective: To characterize the effect of therapeutic and supratherapeutic doses of ampreloxetine on cardiac repolarization in healthy subjects. Background: Ampreloxetine is a potent NE reuptake…Determinants of care partner burden in atypical parkinsonian syndromes
Objective: To understand the determinants of burden among people caring for individuals diagnosed with progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), or multiple system atrophy…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »